Compare Marqeta Inc (MQ) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Tempus AI — how do they compare? Marqeta Inc trades at $17.36 (market cap $1.78B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: Tempus AI is far larger — about 7.2× Marqeta Inc's market cap, and Tempus AI is more actively traded (8,980,490 versus 1,087,097). Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Tempus AI for 22 Days on average.
| MQ | TEM | |
|---|---|---|
Market Cap | $1.78B | $12.77B |
Volume | 1,087,097 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.32 | $99.28 |
52-Week Low | $15.04 | $41.55 |
Typical Hold Time | 44 Days | 22 Days |
Enterprise Value | $1.09B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.06, up 3.08% with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue growth from $507M in 2024 to projected $677M in 2026. Recent partnerships with BVNK for stablecoin cards and Google for wallet expansion highlight strategic growth initiatives. However, valuation metrics remain elevated with a P/E of 189.56 and EV/EBITDA of 52.44 despite modest profitability margins.
MQ presents a mixed outlook with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and enterprise adoption, though faces risks from contract renewals in Q3 2026 and competitive pressure. Analyst consensus of $11.38 suggests caution despite recent bullish earnings revisions and institutional interest in the digital payments space.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
